Cytopathology is one of the most rapidly developing fields in pathology, with significant impact on the diagnostic practice of all organ systems. Its impressive progress not only relies on its minimally invasive nature and cost-effectiveness, but also stems from the clear relationship of its diagnostic categories with risk of malignancy and clinical management, as well as the successful integration of molecular/genetic tests into daily practice. With the increasing clinical demand for less tissue and more specific diagnoses, cytopathology will lead future pathologic development in years to come. In this special section, we capture selected topics in recent cytopathologic progress, including both original studies and timely reviews.One of the most important breakthroughs in cytopathology in 2018 was the establishment and publication of the Milan System for Reporting Salivary Gland Cytopathology.1 The Milan system is based on the studies of many institutions around the globe. In this series, we publish the original article from Temple University (Philadelphia, Pennsylvania) by Luo et al describing their logistics and efforts to build an institutional 6-tier classification system to report salivary gland cytopathology. Slides of 107 salivary gland fine-needle aspirations (FNAs) with subsequent histology slides were reviewed and reclassified using the 6-tier system. The FNA diagnoses were generally consistent with histologic diagnoses for the disease spectrum. The sensitivity, specificity, positive predictive value, and negative predictive value for diagnosing malignancies with this system were 86% (12 of 14), 93% (40 of 43), 80% (12 of 15), and 95% (40 of 42), respectively. The risk of malignancy increased from 0% (0 of 13) for negative for neoplasm to 7% (2 of 29) for benign neoplasm, 67% (2 of 3) for suspicious for malignancy, and 83% (10 of 12) for positive for malignancy. This study points out the rationale and helps to pave the way for the adoption of the Milan System for Reporting Salivary Gland Cytopathology.Cytopathologic materials are a great source for molecular tests critical to guide therapeutic decision-making and accurate diagnoses.2 Doxtader et al describe their experience at the Cleveland Clinic with epidermal growth factor receptor (EGFR) mutation testing by next-generation sequencing and anaplastic lymphoma kinase (ALK) gene rearrangement testing by fluorescence in situ hybridization (FISH) in non–small cell lung carcinomas. At their institution, liquid-based cytology specimens are the primary resource used for molecular testing. In most instances, adequate DNA could be extracted from the residual cell pellets for next-generation sequencing, and ThinPrep slides could be used reliably for FISH testing for ALK gene rearrangements. In occasional cases where the cell pellet material was not adequate for molecular testing, cell blocks and/or surgical pathology specimens were secondary options. In a different original study using an immunocytologic approach, Ren and Klump showed that 87.6% of carcinomas of Müllerian origin in ascites and pleural fluids were positive for PAX8; 19.2%, 18.1%, 23.4%, and 8.5% of high-grade serous carcinomas were positive for GATA3, SOX2, uroplakin II, and SALL4, respectively. Increasing acceptance of molecular tests into cytopathologic practice is also highlighted by a recent recommendation from the International Mesothelioma Interest Group to conduct p16 (by FISH) and BAP1 (by immunohistochemistry) staining in cytologic specimens suspicious for mesothelioma.3The diagnostic power of cytopathology for infectious disease in the lower respiratory tract is highlighted by Baldassarri et al in this series. Cytomorphologic analysis helps to triage and plays a critical supporting role to the microbiology laboratory in prompt and accurate identification of causative organisms, particularly in immunosuppressed patients. Again, cytopathologic materials are perfect for molecular tests including polymerase chain reaction, immunochromatographic assay, and direct antigen detection in identification of bacteria, viruses, and fungal elements.Tremendous progress has been made in the past few years in cytopathology, from the standardized reporting system to FNA sample techniques to molecular tests of tumor-specific markers and specific infectious agents. The continued improvement of cytopathologic practice will undoubtably expand its role in the clinical management of patients.